The European Commission issued a pair of approvals for auto-immune conditions.
UCB nailed approval for Cimzia (certolizumab pegol), used for the treatment of patients with rheumatoid arthritis that have failed DMARDs and traditional therapy. Another option is always a good thing. (Ref: UCB press release)
Following closely, J&J (dba Centocor Ortho Biotech) and Schering-Plough (soon to be Merck) received approval for Simponi (golimumab) for the approval of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. (Ref: AP)
